Dostarlimab Opens Treatment-Only Path in Rectal Cancer
Episode Summary
FDA granted accelerated approval to dostarlimab for untreated MSI-H or dMMR locally advanced rectal cancer, offering eligible patients potential organ preservation while requiring long-term confirmation.